nodes	percent_of_prediction	percent_of_DWPC	metapath
Brimonidine—ADRA2C—attention deficit hyperactivity disorder	0.614	0.701	CbGaD
Brimonidine—ADRA2A—attention deficit hyperactivity disorder	0.262	0.299	CbGaD
Brimonidine—Tizanidine—ADRA2C—attention deficit hyperactivity disorder	0.0023	0.285	CrCbGaD
Brimonidine—Apraclonidine—ADRA2C—attention deficit hyperactivity disorder	0.00224	0.277	CrCbGaD
Brimonidine—Clonidine—ADRA2C—attention deficit hyperactivity disorder	0.00112	0.139	CrCbGaD
Brimonidine—Tizanidine—ADRA2A—attention deficit hyperactivity disorder	0.000981	0.121	CrCbGaD
Brimonidine—Apraclonidine—ADRA2A—attention deficit hyperactivity disorder	0.000956	0.118	CrCbGaD
Brimonidine—Clonidine—ADRA2A—attention deficit hyperactivity disorder	0.000479	0.0593	CrCbGaD
Brimonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.00027	0.00234	CbGpPWpGaD
Brimonidine—ADRA2A—Integration of energy metabolism—CACNA1C—attention deficit hyperactivity disorder	0.000268	0.00232	CbGpPWpGaD
Brimonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.000265	0.00229	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.000263	0.00227	CbGpPWpGaD
Brimonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.000247	0.00214	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.000246	0.00212	CbGpPWpGaD
Brimonidine—ADRA2A—Integration of energy metabolism—SNAP25—attention deficit hyperactivity disorder	0.000234	0.00202	CbGpPWpGaD
Brimonidine—ADRA2A—Platelet activation, signaling and aggregation—ADRA2C—attention deficit hyperactivity disorder	0.000232	0.00201	CbGpPWpGaD
Brimonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.000232	0.002	CbGpPWpGaD
Brimonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.000227	0.00196	CbGpPWpGaD
Brimonidine—ADRA2A—G alpha (i) signalling events—ADRA2C—attention deficit hyperactivity disorder	0.000221	0.00191	CbGpPWpGaD
Brimonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.000212	0.00183	CbGpPWpGaD
Brimonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—ADRA2C—attention deficit hyperactivity disorder	0.000205	0.00177	CbGpPWpGaD
Brimonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD5—attention deficit hyperactivity disorder	0.000201	0.00174	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—GRM7—attention deficit hyperactivity disorder	0.0002	0.00173	CbGpPWpGaD
Brimonidine—ADRA2B—G alpha (i) signalling events—HRH3—attention deficit hyperactivity disorder	0.000198	0.00171	CbGpPWpGaD
Brimonidine—AOX1—Disease—STUB1—attention deficit hyperactivity disorder	0.00019	0.00165	CbGpPWpGaD
Brimonidine—ADRA2C—G alpha (i) signalling events—HRH3—attention deficit hyperactivity disorder	0.000185	0.0016	CbGpPWpGaD
Brimonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.000184	0.00159	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.000176	0.00153	CbGpPWpGaD
Brimonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—ADRA2C—attention deficit hyperactivity disorder	0.000176	0.00152	CbGpPWpGaD
Brimonidine—ADRA2B—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.000173	0.0015	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000173	0.00149	CbGpPWpGaD
Brimonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD5—attention deficit hyperactivity disorder	0.000172	0.00149	CbGpPWpGaD
Brimonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.000172	0.00148	CbGpPWpGaD
Brimonidine—ADRA2C—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.000162	0.0014	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000161	0.0014	CbGpPWpGaD
Brimonidine—ADRA2B—Platelet activation, signaling and aggregation—ADRA2A—attention deficit hyperactivity disorder	0.000161	0.00139	CbGpPWpGaD
Brimonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.000161	0.00139	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—ADRA2C—attention deficit hyperactivity disorder	0.000158	0.00136	CbGpPWpGaD
Brimonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000157	0.00136	CbGpPWpGaD
Brimonidine—ADRA2B—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.000156	0.00135	CbGpPWpGaD
Brimonidine—ADRA2B—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.000153	0.00132	CbGpPWpGaD
Brimonidine—ADRA2B—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.000151	0.00131	CbGpPWpGaD
Brimonidine—ADRA2C—Platelet activation, signaling and aggregation—ADRA2A—attention deficit hyperactivity disorder	0.00015	0.0013	CbGpPWpGaD
Brimonidine—ADRA2A—G alpha (i) signalling events—HRH3—attention deficit hyperactivity disorder	0.00015	0.0013	CbGpPWpGaD
Brimonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.00015	0.0013	CbGpPWpGaD
Brimonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000149	0.00129	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000149	0.00128	CbGpPWpGaD
Brimonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000147	0.00127	CbGpPWpGaD
Brimonidine—ADRA2C—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.000145	0.00126	CbGpPWpGaD
Brimonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000145	0.00125	CbGpPWpGaD
Brimonidine—ADRA2C—G alpha (i) signalling events—ADRA2A—attention deficit hyperactivity disorder	0.000143	0.00124	CbGpPWpGaD
Brimonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000142	0.00123	CbGpPWpGaD
Brimonidine—ADRA2C—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.000141	0.00122	CbGpPWpGaD
Brimonidine—ADRA2B—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.000141	0.00122	CbGpPWpGaD
Brimonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.00014	0.00121	CbGpPWpGaD
Brimonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000139	0.0012	CbGpPWpGaD
Brimonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—HRH3—attention deficit hyperactivity disorder	0.000139	0.0012	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000139	0.0012	CbGpPWpGaD
Brimonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000138	0.00119	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—ADRA2C—attention deficit hyperactivity disorder	0.000137	0.00118	CbGpPWpGaD
Brimonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.000135	0.00117	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000135	0.00117	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—ADRA2C—attention deficit hyperactivity disorder	0.000134	0.00116	CbGpPWpGaD
Brimonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—ADRA2A—attention deficit hyperactivity disorder	0.000133	0.00115	CbGpPWpGaD
Brimonidine—ADRA2C—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.000132	0.00114	CbGpPWpGaD
Brimonidine—ADRA2A—G alpha (i) signalling events—HTR1B—attention deficit hyperactivity disorder	0.000131	0.00113	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—DRD5—attention deficit hyperactivity disorder	0.000131	0.00113	CbGpPWpGaD
Brimonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000131	0.00113	CbGpPWpGaD
Brimonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000131	0.00113	CbGpPWpGaD
Brimonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000128	0.00111	CbGpPWpGaD
Brimonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000128	0.00111	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000126	0.00109	CbGpPWpGaD
Brimonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000124	0.00107	CbGpPWpGaD
Brimonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	0.000122	0.00106	CbGpPWpGaD
Brimonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR1B—attention deficit hyperactivity disorder	0.000122	0.00105	CbGpPWpGaD
Brimonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000122	0.00105	CbGpPWpGaD
Brimonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.00012	0.00104	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.00012	0.00104	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—ADRA2C—attention deficit hyperactivity disorder	0.00012	0.00103	CbGpPWpGaD
Brimonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	0.000119	0.00103	CbGpPWpGaD
Brimonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HRH3—attention deficit hyperactivity disorder	0.000119	0.00103	CbGpPWpGaD
Brimonidine—ADRA2A—G alpha (i) signalling events—DRD3—attention deficit hyperactivity disorder	0.000118	0.00102	CbGpPWpGaD
Brimonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	0.000116	0.001	CbGpPWpGaD
Brimonidine—ADRA2A—G alpha (i) signalling events—DRD4—attention deficit hyperactivity disorder	0.000115	0.000991	CbGpPWpGaD
Brimonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—ADRA2A—attention deficit hyperactivity disorder	0.000114	0.000983	CbGpPWpGaD
Brimonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD1—attention deficit hyperactivity disorder	0.000113	0.000979	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—GRM7—attention deficit hyperactivity disorder	0.000113	0.000975	CbGpPWpGaD
Brimonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	0.000112	0.000971	CbGpPWpGaD
Brimonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000112	0.000968	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	0.000112	0.000967	CbGpPWpGaD
Brimonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD3—attention deficit hyperactivity disorder	0.00011	0.000948	CbGpPWpGaD
Brimonidine—ADRA2A—G alpha (i) signalling events—DRD2—attention deficit hyperactivity disorder	0.000107	0.000924	CbGpPWpGaD
Brimonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD4—attention deficit hyperactivity disorder	0.000106	0.00092	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	0.000105	0.000905	CbGpPWpGaD
Brimonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	0.000105	0.000904	CbGpPWpGaD
Brimonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR1B—attention deficit hyperactivity disorder	0.000104	0.000902	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—GRM7—attention deficit hyperactivity disorder	0.000102	0.000885	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	9.97e-05	0.000862	CbGpPWpGaD
Brimonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD2—attention deficit hyperactivity disorder	9.92e-05	0.000857	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	9.78e-05	0.000846	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	9.77e-05	0.000844	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	9.74e-05	0.000842	CbGpPWpGaD
Brimonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD1—attention deficit hyperactivity disorder	9.7e-05	0.000838	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—TPH2—attention deficit hyperactivity disorder	9.46e-05	0.000817	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—CACNB2—attention deficit hyperactivity disorder	9.46e-05	0.000817	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	9.43e-05	0.000815	CbGpPWpGaD
Brimonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD3—attention deficit hyperactivity disorder	9.4e-05	0.000812	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—DPYD—attention deficit hyperactivity disorder	9.3e-05	0.000804	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	9.27e-05	0.000801	CbGpPWpGaD
Brimonidine—ADRA2B—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	9.15e-05	0.000791	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	9.15e-05	0.000791	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	9.13e-05	0.000789	CbGpPWpGaD
Brimonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—attention deficit hyperactivity disorder	9.12e-05	0.000788	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	9.1e-05	0.000786	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—HRH3—attention deficit hyperactivity disorder	9.09e-05	0.000786	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	9.06e-05	0.000783	CbGpPWpGaD
Brimonidine—AOX1—Disease—SNAP25—attention deficit hyperactivity disorder	9.03e-05	0.00078	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	8.87e-05	0.000767	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	8.81e-05	0.000761	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—ADRA2A—attention deficit hyperactivity disorder	8.66e-05	0.000748	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—CACNA1C—attention deficit hyperactivity disorder	8.65e-05	0.000748	CbGpPWpGaD
Brimonidine—ADRA2C—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	8.55e-05	0.000739	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	8.55e-05	0.000739	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	8.53e-05	0.000737	CbGpPWpGaD
Brimonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—attention deficit hyperactivity disorder	8.5e-05	0.000734	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	8.29e-05	0.000716	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	8.29e-05	0.000716	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	7.98e-05	0.000689	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	7.97e-05	0.000688	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—HTR1B—attention deficit hyperactivity disorder	7.95e-05	0.000687	CbGpPWpGaD
Brimonidine—ADRA2B—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	7.84e-05	0.000678	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—ADRA2A—attention deficit hyperactivity disorder	7.74e-05	0.000669	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—ADRA2C—attention deficit hyperactivity disorder	7.57e-05	0.000654	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—SNAP25—attention deficit hyperactivity disorder	7.56e-05	0.000653	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	7.45e-05	0.000644	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—DRD5—attention deficit hyperactivity disorder	7.41e-05	0.000641	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—DRD1—attention deficit hyperactivity disorder	7.39e-05	0.000638	CbGpPWpGaD
Brimonidine—ADRA2C—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	7.33e-05	0.000633	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—ADRA2A—attention deficit hyperactivity disorder	7.2e-05	0.000622	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—DRD3—attention deficit hyperactivity disorder	7.15e-05	0.000618	CbGpPWpGaD
Brimonidine—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—attention deficit hyperactivity disorder	6.95e-05	0.0006	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—DRD4—attention deficit hyperactivity disorder	6.95e-05	0.0006	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—ADRA2C—attention deficit hyperactivity disorder	6.87e-05	0.000594	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	6.77e-05	0.000585	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—DRD5—attention deficit hyperactivity disorder	6.73e-05	0.000582	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—DRD2—attention deficit hyperactivity disorder	6.47e-05	0.000559	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	6.33e-05	0.000547	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	6.23e-05	0.000538	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	6.15e-05	0.000531	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—GRM7—attention deficit hyperactivity disorder	6.05e-05	0.000523	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	5.97e-05	0.000516	CbGpPWpGaD
Brimonidine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—attention deficit hyperactivity disorder	5.95e-05	0.000514	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	5.92e-05	0.000512	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	5.82e-05	0.000503	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	5.74e-05	0.000496	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—COMT—attention deficit hyperactivity disorder	5.73e-05	0.000495	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—MAOA—attention deficit hyperactivity disorder	5.69e-05	0.000492	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	5.58e-05	0.000482	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	5.53e-05	0.000478	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	5.5e-05	0.000476	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	5.37e-05	0.000465	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	5.35e-05	0.000462	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	5.33e-05	0.000461	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	5.24e-05	0.000453	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	5.24e-05	0.000453	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	5.17e-05	0.000447	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	5.14e-05	0.000444	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	5.14e-05	0.000444	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—HRH3—attention deficit hyperactivity disorder	5.14e-05	0.000444	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	5.02e-05	0.000434	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	5e-05	0.000432	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.98e-05	0.00043	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	4.9e-05	0.000423	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—ADRA2A—attention deficit hyperactivity disorder	4.89e-05	0.000423	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—ADRA2C—attention deficit hyperactivity disorder	4.85e-05	0.00042	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	4.84e-05	0.000418	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	4.83e-05	0.000418	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	4.82e-05	0.000417	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	4.8e-05	0.000415	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	4.76e-05	0.000411	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—STUB1—attention deficit hyperactivity disorder	4.72e-05	0.000408	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	4.7e-05	0.000406	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	4.67e-05	0.000403	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—HRH3—attention deficit hyperactivity disorder	4.67e-05	0.000403	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR ligand binding—HTR2A—attention deficit hyperactivity disorder	4.53e-05	0.000392	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	4.52e-05	0.000391	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	4.5e-05	0.000389	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—HTR1B—attention deficit hyperactivity disorder	4.49e-05	0.000388	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—ADRA2A—attention deficit hyperactivity disorder	4.44e-05	0.000384	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	4.39e-05	0.000379	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	4.38e-05	0.000378	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—DRD1—attention deficit hyperactivity disorder	4.17e-05	0.000361	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—TPH2—attention deficit hyperactivity disorder	4.12e-05	0.000356	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—CACNB2—attention deficit hyperactivity disorder	4.12e-05	0.000356	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	4.09e-05	0.000353	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—HTR1B—attention deficit hyperactivity disorder	4.08e-05	0.000352	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—ADRA2C—attention deficit hyperactivity disorder	4.06e-05	0.000351	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—DPYD—attention deficit hyperactivity disorder	4.06e-05	0.000351	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—DRD3—attention deficit hyperactivity disorder	4.04e-05	0.000349	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—DRD5—attention deficit hyperactivity disorder	3.98e-05	0.000344	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—DRD4—attention deficit hyperactivity disorder	3.93e-05	0.000339	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—RTN4—attention deficit hyperactivity disorder	3.9e-05	0.000337	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—DRD1—attention deficit hyperactivity disorder	3.79e-05	0.000328	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.77e-05	0.000326	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—DRD3—attention deficit hyperactivity disorder	3.67e-05	0.000317	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—DRD2—attention deficit hyperactivity disorder	3.66e-05	0.000316	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.63e-05	0.000314	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—DRD4—attention deficit hyperactivity disorder	3.56e-05	0.000308	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	3.39e-05	0.000293	CbGpPWpGaD
Brimonidine—ADRA2B—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	3.38e-05	0.000292	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—TPH2—attention deficit hyperactivity disorder	3.35e-05	0.00029	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CACNB2—attention deficit hyperactivity disorder	3.35e-05	0.00029	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—DRD2—attention deficit hyperactivity disorder	3.32e-05	0.000287	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—SNAP25—attention deficit hyperactivity disorder	3.3e-05	0.000285	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—DPYD—attention deficit hyperactivity disorder	3.3e-05	0.000285	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	3.18e-05	0.000274	CbGpPWpGaD
Brimonidine—ADRA2C—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	3.15e-05	0.000273	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—ADRA2A—attention deficit hyperactivity disorder	3.14e-05	0.000271	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	3.07e-05	0.000265	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—CACNA1C—attention deficit hyperactivity disorder	3.06e-05	0.000265	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.97e-05	0.000256	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.95e-05	0.000255	CbGpPWpGaD
Brimonidine—AOX1—Disease—EP300—attention deficit hyperactivity disorder	2.93e-05	0.000254	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.86e-05	0.000247	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.86e-05	0.000247	CbGpPWpGaD
Brimonidine—ADRA2B—Hemostasis—EP300—attention deficit hyperactivity disorder	2.83e-05	0.000245	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.81e-05	0.000243	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.78e-05	0.00024	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.76e-05	0.000238	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HRH3—attention deficit hyperactivity disorder	2.76e-05	0.000238	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—SNAP25—attention deficit hyperactivity disorder	2.68e-05	0.000231	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.67e-05	0.000231	CbGpPWpGaD
Brimonidine—ADRA2C—Hemostasis—EP300—attention deficit hyperactivity disorder	2.64e-05	0.000228	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—ADRA2A—attention deficit hyperactivity disorder	2.62e-05	0.000227	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.59e-05	0.000224	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.59e-05	0.000223	CbGpPWpGaD
Brimonidine—ADRA2A—GPCR downstream signaling—HTR2A—attention deficit hyperactivity disorder	2.56e-05	0.000221	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—COMT—attention deficit hyperactivity disorder	2.5e-05	0.000216	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—MAOA—attention deficit hyperactivity disorder	2.48e-05	0.000214	CbGpPWpGaD
Brimonidine—AOX1—Metabolism—EP300—attention deficit hyperactivity disorder	2.46e-05	0.000212	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	2.41e-05	0.000209	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HTR1B—attention deficit hyperactivity disorder	2.41e-05	0.000208	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling by GPCR—HTR2A—attention deficit hyperactivity disorder	2.33e-05	0.000201	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—DRD1—attention deficit hyperactivity disorder	2.24e-05	0.000194	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—DRD3—attention deficit hyperactivity disorder	2.17e-05	0.000187	CbGpPWpGaD
Brimonidine—ADRA2A—Hemostasis—EP300—attention deficit hyperactivity disorder	2.15e-05	0.000186	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—DRD4—attention deficit hyperactivity disorder	2.11e-05	0.000182	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—COMT—attention deficit hyperactivity disorder	2.03e-05	0.000175	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—MAOA—attention deficit hyperactivity disorder	2.02e-05	0.000174	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—DRD2—attention deficit hyperactivity disorder	1.96e-05	0.00017	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.81e-05	0.000156	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.69e-05	0.000146	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—HTR2A—attention deficit hyperactivity disorder	1.37e-05	0.000119	CbGpPWpGaD
Brimonidine—ADRA2C—Metabolism—EP300—attention deficit hyperactivity disorder	1.07e-05	9.26e-05	CbGpPWpGaD
Brimonidine—ADRA2B—Signaling Pathways—EP300—attention deficit hyperactivity disorder	9.59e-06	8.29e-05	CbGpPWpGaD
Brimonidine—ADRA2C—Signaling Pathways—EP300—attention deficit hyperactivity disorder	8.96e-06	7.74e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Metabolism—EP300—attention deficit hyperactivity disorder	8.7e-06	7.52e-05	CbGpPWpGaD
Brimonidine—ADRA2A—Signaling Pathways—EP300—attention deficit hyperactivity disorder	7.28e-06	6.29e-05	CbGpPWpGaD
